Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
A Trial of Intermittent Treatment in the Prevention of Malaria in Senegalese Children
This study has been completed.
Sponsors and Collaborators: Gates Malaria Partnership
IRD, Dakar, Senegal.
IRD, Montpellier, France.
Universite Cheikh Anta Diop, Dakar, Senegal
Ministry of Health, Senegal
Information provided by: Gates Malaria Partnership
ClinicalTrials.gov Identifier: NCT00132561
  Purpose

In countries of the Sahel and sub-Sahel, malaria transmission is highly seasonal with nearly all infections occurring during a few months of the year. However, mortality and morbidity from malaria may be high during this period, especially in young children who are the group most at risk.

Intermittent preventative treatment (IPT) is a new approach to the prevention of malaria in this situation. IPT involves the administration of an anti-malarial to children at risk for malaria at fixed times, even if they are not infected. To investigate how effective this approach might be in Senegal, a trial has been undertaken in which 1136 children aged 6 weeks to 59 months were given a single dose of sulfadoxine pyrimethamine and artesunate on three occasions during a three-month rainy season and the incidence of clinical malaria in these children was compared with that in a group of children who received placebo. Additional observations were made on the incidence of side effects in children in the two groups and on the impact of IPT in children (IPTc) on markers of drug resistance in children whose blood films were positive for Plasmodium falciparum.


Condition Intervention Phase
Malaria
Drug: Sulfadoxine/pyrimethamine and artesunate
Phase II
Phase III

MedlinePlus related topics: Malaria
Drug Information available for: Pyrimethamine Sulfadoxine Artesunate
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study
Official Title: A Double-Blind, Randomised, Placebo-Controlled Trial to Measure the Potential of Intermittent Treatment With Artesunate Plus Sulphadoxine/Pyrimethamine (SP) to Reduce the Malaria Burden in Sub-Saharan Africa

Further study details as provided by Gates Malaria Partnership:

Primary Outcome Measures:
  • Clinical episodes of malaria

Secondary Outcome Measures:
  • Side effects
  • Change in the prevalence of drug resistance markers

Estimated Enrollment: 1200
Study Start Date: June 2002
Estimated Study Completion Date: December 2003
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   6 Weeks to 59 Months
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Ages 6 weeks to 59 months
  • Residence in the study area
  • Informed consent

Exclusion Criteria:

  • Known allergy to study drugs
  • Serious underlying illness
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00132561

Locations
Senegal
Institut de recherche pour le developpement
Dakar, Senegal, BP 1386
Sponsors and Collaborators
Gates Malaria Partnership
IRD, Dakar, Senegal.
IRD, Montpellier, France.
Universite Cheikh Anta Diop, Dakar, Senegal
Ministry of Health, Senegal
Investigators
Principal Investigator: Badara Cisse, MD IRD, Dakar, Senegal.
  More Information

Gates Malaria Partnership website  This link exits the ClinicalTrials.gov site

Publications of Results:
Study ID Numbers: ITCR 5094
Study First Received: August 18, 2005
Last Updated: May 3, 2006
ClinicalTrials.gov Identifier: NCT00132561  
Health Authority: Senegal: Ministere de la sante

Study placed in the following topic categories:
Folic Acid
Artesunate
Pyrimethamine
Protozoan Infections
Parasitic Diseases
Malaria
Sulfadoxine

Additional relevant MeSH terms:
Anti-Infective Agents
Antiprotozoal Agents
Molecular Mechanisms of Pharmacological Action
Coccidiosis
Enzyme Inhibitors
Anti-Infective Agents, Urinary
Folic Acid Antagonists
Renal Agents
Pharmacologic Actions
Antimalarials
Antiparasitic Agents
Therapeutic Uses
Amebicides

ClinicalTrials.gov processed this record on January 14, 2009